多西紫杉醇联合奈达铂治疗放疗后复发或转移鼻咽癌的疗效观察

目的:观察多西紫杉醇联合奈达铂治疗~(60)Co-γ根治性放疗后复发或转移鼻咽癌的近期疗效和毒副反应。方法:采用回顾性对照研究方法,其中观察组给予多西紫杉醇75mg.m-2,静脉滴注1h,第1天;奈达铂80mg.m-2,静脉滴注2h,第2天。对照组给予顺铂30mg.m-2.d-1,静脉滴注,第1～3天;5-氟尿嘧啶1.0g.m-2.d-1加入百特泵中持续静脉滴注4d。21d为一疗程。结果:观察组治疗20例,总有效率为70.0%,临床受益率为90.0%,耐受性好;对照组15例,总有效率为46.7%,临床受益率为80.0%。2组总有效率、临床受益率差异均无统计学意义(P>0.05)。结论:多西紫杉醇联合奈达铂治疗放疗后复发或转移鼻咽癌的总有效率和临床受益率较传统顺铂联合5-氟尿嘧啶方案高,但无统计学差异,临床耐受性好。

Efficacy of Docetaxel in Combination with Nedaplatin for Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma Following Radiotherapy

OBJECTIVE： To evaluate the short term efficacy and side effects of Docetaxel in combination with Nedaplatin for patients with recurrent and metastatic nasopharyngeal neoplasms following radical radiotherapy （^60Co-γ） METHODS： In this retrospective control study, the experimental group received Docetaxel（75 mg·m^-2） by drip infusion for 1 hour on day 1 followed by drip infusion of Nedaplatin（80mg·m^-2） for 2 hours on day 2, while the control group received DDP （30mg·m^2·d^-1） by drip infusion from day l to day 3 in combination with 5-1cU （1.0g·m^2·d^-1） by drip infusion for4 days. One course of treatment was completed in 21 days. RESULTS： In the experimental group（ n = 20 patients）, the overall response rate was 70.0% and the clinical benefit rate was 90.0%, and good tolerance was achieved; in the control group（n = 15）, the overall response rate was 46.7% and the clinical benefit rate was 80.0%. There were no significant differences in overall response rate and clinical benefit rate between the two groups（P 〉 0.05） . CONCLUSION： Docetaxel in combination with Nedaplatin is more effective than the traditional DDP in combination with 5 - FU in total response rate and clinical benefit rate for patients with recurrent and metastatic nasopharyngeal neoplasms following radical radiotherapy （^60Co-γ）, yet the differences were nonsignificant. Moreover, Docetaxel in combination with Nedaplatin is well - tolerated in patients.